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It has come to the publisher’s attention that the origi-
nal version of this article [1] unfortunately contained an 
unnecessarily complicated version of the data in Table 1. 




*Correspondence:  dj_morre@yahoo.com 
1 MorNuCo, Inc, Purdue University Research Park, 1201B Cumberland 
Avenue, West Lafayette, IN, USA
Full list of author information is available at the end of the article
Page 2 of 2Morré et al. Clin Proteom  (2016) 13:3 
Author details
1 MorNuCo, Inc, Purdue University Research Park, 1201B Cumberland Avenue, 
West Lafayette, IN, USA. 2 National Centre for Asbestos Related Disease, Univer-
sity of Western Australia, Perth, Australia. 3 School of Medicine and Pharmacol-
ogy, University of Western Australia, Perth, Australia. 4 Department of Respira-
tory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia. 5 School 
of Population Health, University of Western Australia, Perth, Australia. 
Reference
 1. Morré DJ, Hostetler B, Taggart DJ, Morré DM, Musk AW, Robinson BWS, 
Creaney J. ENOX2-based early detection (ONCOblot) of asbestos-induced 
malignant mesothelioma 4–10 years in advance of clinical symptoms. 
Clin Proteom. 2016;13:2.
Table 1 Range of molecular weights and isoelectric points (99th percentile) of ENOX2 transcript variants for 16 common 
cancer types compared with mesothelioma [Unpublished data from the ONCOblot Tissue of Origin Database, MorNuCo, 
Inc]
a Includes leukemia, lymphoma and myeloma
b Present study
Cancer N Acceptable ranges
Protein 1 Protein 2 Protein 3
MW (kDa) pI (pH) MW (kDa) pI (pH) MW (kDa) pI (pH)
Bladder 25 63–66 4.2–5.6 42–48 4.1–4.8
Blood cella 82 34–47 3.5–4.5
Breast 538 64–69 4.2–4.9
Cervical 37 90–100 4.2–5.4
Colorectal 90 80–96 4.4–5.4 50–65 4.2–5.3 33–46 3.8–5.2
Endometrial (uterine) 43 67–71 4.2–5.1 41–48 3.7–5.4
Gastric 10 120–188 4.7–5.5 50–62 4.5–5.6 45–53 2.4–3.6
Hepatocellular 19 58–70 4.5–5.0 34–40 4.1–5.2
Lung 200 52–56 4.1–5.3
Melanoma 39 37–41 4.6–5.3
Mesotheliomab 18 60–68 3.8–4.1 38–44 3.8–4.6
Ovarian 98 72–90 3.7–5.0 37–47 3.7–5.0
Pancreatic 61 49–51 3.9–5.4
Prostate 178 71–88 5.1–6.5
Kidney (renal cell) 21 69–73 4.7–5.4 54–61 4.1–5.2 38–43 3.7–4.3
Sarcoma 20 50–55 5.2–5.6 37–45 4.3–4.9
Squamous cell 41 57–68 5.0–5.4
Total 1520
The online version of the original article can be found under 
doi:10.1186/s12014-016-9103-3.
